![Martin J. Small](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Profiel
Martin J.
Small worked as a Director of New Projects at ReGen Therapeutics Plc from 1998 to 2011.
He also worked as a Director at Alexander David Investments Plc in 2011.
Eerdere bekende functies van Martin J. Small
Bedrijven | Functie | Einde |
---|---|---|
ReGen Therapeutics Plc
![]() ReGen Therapeutics Plc Pharmaceuticals: MajorHealth Technology ReGen Therapeutics Plc develops healthcare nutraceutical and ethical pharmaceuticals. Its principal activity is research and development of a drug product called Colostrinin for the treatment for Alzheimer's disease and other neurological disorders. It also involves in the development of Colostrinin peptides as pharmaceutical drug candidates for the treatment of Alzheimer's disease and obesity. ReGen Therapeutics Plc conducts pharmacokinetic and pharmacodynamic research. The company was founded on February 11, 1998 and is headquartered in London, the United Kingdom. | Corporate Officer/Principal | 23-02-2011 |
Alexander David Investments Plc
![]() Alexander David Investments Plc Financial ConglomeratesFinance Alexander David Investments Plc operates as an investment company. Its investment targets are small cap and special opportunities with a current bias towards basic resources and oil and gas sectors. The company was founded on February 11, 1998 and is headquartered in London, the United Kingdom. | Directeur/Bestuurslid | 10-02-2011 |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
Bedrijven in privébezit | 2 |
---|---|
ReGen Therapeutics Plc
![]() ReGen Therapeutics Plc Pharmaceuticals: MajorHealth Technology ReGen Therapeutics Plc develops healthcare nutraceutical and ethical pharmaceuticals. Its principal activity is research and development of a drug product called Colostrinin for the treatment for Alzheimer's disease and other neurological disorders. It also involves in the development of Colostrinin peptides as pharmaceutical drug candidates for the treatment of Alzheimer's disease and obesity. ReGen Therapeutics Plc conducts pharmacokinetic and pharmacodynamic research. The company was founded on February 11, 1998 and is headquartered in London, the United Kingdom. | Health Technology |
Alexander David Investments Plc
![]() Alexander David Investments Plc Financial ConglomeratesFinance Alexander David Investments Plc operates as an investment company. Its investment targets are small cap and special opportunities with a current bias towards basic resources and oil and gas sectors. The company was founded on February 11, 1998 and is headquartered in London, the United Kingdom. | Finance |